Lipid management in 13,000 high risk cardiovascular patients treated under daily practice conditions: LIMA Registry

References

• World Health OrganizationThe Global Burden of Disease: 2004 UpdateGenevaWorld Health Organization2008 Available from: http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.htmlAccessed September 13, 2012
   Google Scholar
• Centers for Disease Control and Prevention (CDC)QuickStats: Age-adjusted death rates for heart disease and cancer – United States, 1999–2009*MMWR [series on the Internet]620116021713 Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6021a6.htm?s_cid=mm6021a6_wAccessed November 28, 2012
   Google Scholar
• GoldsteinLBAdamsRAlbertsMJPrimary prevention of ischemic stroke. A guideline from the American Heart Association/American Stroke Association Stroke Council:Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guidelineStroke20063761583163316675728
   PubMed Web of Science ®Google Scholar
• GreenlandPAlpertJSBellerGA2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive summary. A report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic ResonanceJ Am Coll Cardiol2010562521822199
   Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in AdultsExecutive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)JAMA2001285192486249711368702
   PubMed Web of Science ®Google Scholar
• KloseGSchwabeULipidsenkende Mittel. [Lipid lowering drugs]SchwabeUPaffrathDArzneiverordnungs-Report 2011BerlinSpringer2010683698 German.
   Google Scholar
• PhillipsLSBranchWTCookCBClinical inertiaAnn Intern Med2001135982583411694107
   PubMed Web of Science ®Google Scholar
• CabanaMDRandCSPoweNRWhy don’t physicians follow clinical practice guidelines? A framework for improvementJAMA1999282151458146510535437
   PubMed Web of Science ®Google Scholar
• BestehornKSchäferJGittALeitliniengerechte Lipidtherapie und Zielwerterreichung bei Risikopatienten im klinischen Alltag. Rationale, Ziele und Design des LIMA-registers [LIMA-register: rationale, aims and design]MMW Fortschr Med2008150Suppl 3S135S141 German.
   PubMedGoogle Scholar
• SonntagFSchaeferJRGittAKLipidtherapie im Alltag (LIMA): Leitliniengerechtes Lipidmanagement bei Patienten mit hohem kardiovaskulären Risiko in der klinischen Praxis (LIMA Register) [Lipid therapy in daily routine. Guidelines compatible lipid management of patients with high cardiovascular risk in clinical practice (LIMA registry)]Dtsch med Wochenschr20121374020472052 German.23023622
   PubMedGoogle Scholar
• Good Epidemiological Practice (GEP): Proper conduct in epidemiologic researchUpdated 2007. International Epidemiological Association2007[updated April 24, 2010] Available from: http://ieaweb.org/2010/04/good-epidemiological-practice-gep/Accessed November 28, 2012
   Google Scholar
• NorgrenLHiattWRDormandyJATASC II Working GroupInter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)Eur J Vasc Endovasc Surg200733Suppl 1S1S7517140820
   PubMed Web of Science ®Google Scholar
• GittAKJüngerCSmolkaWBestehornKPrevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in GermanyClin Res Cardiol2010991172373320521058
   PubMed Web of Science ®Google Scholar
• YusufSHawkenSOunpuuSINTERHEART Study InvestigatorsEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyLancet2004364943893795215364185
   PubMed Web of Science ®Google Scholar
• BaigentCKeechAKearneyPMCholesterol Treatment Trialists’ (CTT) CollaboratorsEfficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet200536694931267127816214597
   PubMed Web of Science ®Google Scholar
• LawMRWaldNJRudnickaARQuantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysisBMJ200332674041423142712829554
   PubMed Web of Science ®Google Scholar
• LeeJMSChoudhuryRPProspects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targetsHeart200793555956416449520
   PubMed Web of Science ®Google Scholar
• GittAKJuengerCJannowitzCKarmannBSengesJBestehornKGuideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registryEur J Cardiovasc Prev Rehabil200916443844419369876
   PubMedGoogle Scholar
• SagerHBLinsel-NitschkePMayerBPhysicians’ perception of guideline-recommended low-density lipoprotein target values: characteristics of misclassified patientsEur Heart J201031101266127320219745
   PubMed Web of Science ®Google Scholar
• HaywardRAKrumholzHMThree reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institute of HealthCirc Cardiovasc Qual Outcomes2012512522253366
   PubMed Web of Science ®Google Scholar
• BuykenAEvon EckardsteinASchulteHCullenPAssmannGType 2 diabetes mellitus and risk of coronary heart disease: results of the 10-year follow-up of the PROCAM studyEur J Cardiovasc Prev Rehabil200714223023617446801
   PubMedGoogle Scholar
• SaelyCHAczelSKochLDiabetes as a coronary artery disease risk equivalent: before a change of paradigm?Eur J Cardiovasc Prev Rehabil2010171949919940780
   PubMedGoogle Scholar
• BulugahapitiyaUSiyambalapitiyaSSitholeJIdrisIIs diabetes a coronary risk equivalent? Systematic review and meta-analysisDiabet Med200926214214819236616
   PubMed Web of Science ®Google Scholar
• SchrammTKGislasonGHKøberLDiabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million peopleCirculation2008117151945195418378618
   PubMed Web of Science ®Google Scholar
• Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative GroupArmitageJBowmanLWallendszusKIntensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trialLancet201037697531658166921067805
   PubMed Web of Science ®Google Scholar
• FDA: Limit use of 80 mg simvastatinUS Food and Drug Administration2011[updated June 8, 2011] Available from: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm257884.htmAccessed November 28, 2012
   Google Scholar
• KnoppRHDrug treatment of lipid disordersN Engl J Med1999341749851110441607
   PubMed Web of Science ®Google Scholar
• FDA drug safety communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injuryUS Food and Drug Administration2011[updated June 8, 2011] Available from: http://www.fda.gov/Drugs/DrugSafety/ucm256581.htmAccessed November 28, 2012
   Google Scholar
• MikhailidisDPLawsonRWMcCormickALComparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysisCurr Med Res Opin20112761191121021473671
   PubMed Web of Science ®Google Scholar
• ZeymerUDechendRDeegE3A Registry InvestigatorsAliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registryInt J Clin Pract201266325126122321062
   PubMed Web of Science ®Google Scholar
• ZeymerUSengesJParhoferKGRötherJRisk factors and event rates in patients with atherothrombotic disease in Germany: Results of the REACH registryDtsch Arztebl Int20081054576977519578408
   PubMed Web of Science ®Google Scholar
• IjiomaNRobinsonJGLipid-lowering effects of ezetimibe and simvastatin in combinationExpert Rev Cardiovasc Ther20119213114521453210
   PubMedGoogle Scholar
• ChapmanRHBennerJSPetrillaAAPredictors of adherence with antihypertensive and lipid-lowering therapyArch Intern Med2005165101147115215911728
   PubMedGoogle Scholar
• PittrowDStallaGKZeiherAMPrävalenz, medikamentöse Behandlung und Einstellung des Diabetes mellitus in der Hausarzt-praxis. [Prevalence, drug treatment and metabolic control of diabetes mellitus in primary care]Med Klin (Munich)20061018635644 German.16896570
   PubMedGoogle Scholar
• BestehornKJannowitzCKarmannBPittrowDKirchWCharacteristics, management and attainment of lipid target levels in diabetic and cardiac patients enrolled in Disease Management Program versus those in routine care: LUTZ registryBMC Public Health2009928019653899
   PubMed Web of Science ®Google Scholar
• PsatyBMKoepsellTDLinDAssessment and control for confounding by indication in observational studiesJ Am Geriatr Soc199947674975410366179
   PubMed Web of Science ®Google Scholar